Jaguar Health (JAGX) CEO receives new RSU and stock option grants

Rhea-AI Filing Summary

Jaguar Health, Inc. reported an equity compensation grant to Chief Executive Officer and President Lisa A. Conte, who is also a director. On December 11, 2025, she received 28,592 restricted stock units of common stock at a price of $0, increasing her directly owned common shares to 29,258. Each unit represents one share and will vest on December 11, 2026, with shares delivered on that date.

On the same date, she was granted stock options for 28,592 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. These options vest ratably on a monthly basis over 12 months from the grant date, contingent on her continued employment, and were issued under the company’s 2014 Stock Incentive Plan.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider CONTE LISA A

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	28,592	$0.00	--
Grant/Award	Common Stock	28,592	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 28,592 shares (Direct); Common Stock — 29,258 shares (Direct)

Footnotes (1)

1. Granted pursuant to the issuer's 2014 Stock Incentive Plan. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CONTE LISA A

(Last) (First) (Middle)

C/O JAGUAR HEALTH, INC.

200 PINE ST., STE 400

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jaguar Health, Inc. [ JAGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	12/11/2025(2)(3)		A		28,592	A	$0	29,258	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$1.44	12/11/2025(2)		A		28,592		(4)	12/11/2035	Common Stock	28,592	$0	28,592	D

Explanation of Responses:

1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.

2. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

3. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

4. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

Remarks:

Chief Exec. Officer & President

	/s/ Lisa A. Conte	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Jaguar Health (JAGX) grant to Lisa A. Conte?

On December 11, 2025, Jaguar Health granted Lisa A. Conte 28,592 restricted stock units and stock options for 28,592 shares of common stock.

What is the vesting schedule for Lisa Contes restricted stock units at Jaguar Health (JAGX)?

Each restricted stock unit represents one share of voting common stock and will vest on December 11, 2026, with vested shares delivered on that date.

What are the key terms of Lisa Contes stock options from Jaguar Health (JAGX)?

Lisa Conte received 28,592 stock options with an exercise price of $1.44 per share, expiring on December 11, 2035, vesting monthly over 12 months.

How many Jaguar Health (JAGX) common shares does Lisa Conte own after this Form 4 transaction?

Following the grant of restricted stock units, Lisa Conte beneficially owns 29,258 shares of Jaguar Health common stock directly.

Under which plan were Lisa Contes Jaguar Health (JAGX) awards granted?

Both the restricted stock units and stock options were granted under Jaguar Healths 2014 Stock Incentive Plan.

What roles does Lisa A. Conte hold at Jaguar Health (JAGX)?

Lisa A. Conte is reported as a Director and an Officer, with the remarks identifying her as Chief Executive Officer & President.